Akebia Therapeutics Inc (NASDAQ:AKBA) Receives $14.50 Consensus Price Target from Analysts

Retrieved on: 2019-07-07 19:03:45

Tags for this article:

Click the tags to see associated articles and topics

Akebia Therapeutics Inc (NASDAQ:AKBA) Receives $14.50 Consensus Price Target from Analysts. View article details on hiswai:

Excerpt

<div><b>Baupost Group</b> LLC MA acquired a new stake in Akebia Therapeutics in the 4th quarter valued at approximately $135,327,000. BlackRock Inc. raised ...</div>

Article found on:

View Original Article